Muscular Dystrophy

(asked on 30th October 2017) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if he will make it his policy to ensure that NHS England and Sarepta Therapeutics conduct pricing negotiations at an early stage in the evaluation of Exondys 51.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 2nd November 2017

The National Institute for Health and Care Excellence (NICE) highly specialised technology (HST) evaluation process for eteplirsen (Exondys 51) allows the company to propose a Patient Access Scheme to the Department, or to discuss commercial arrangements with NHS England, if required. The process provides sufficient time to ensure the evaluation is completed on schedule.

Reticulating Splines